AR044283A1 - Procedimeinto para preparar compuestos de espirolactona - Google Patents

Procedimeinto para preparar compuestos de espirolactona

Info

Publication number
AR044283A1
AR044283A1 ARP040101583A ARP040101583A AR044283A1 AR 044283 A1 AR044283 A1 AR 044283A1 AR P040101583 A ARP040101583 A AR P040101583A AR P040101583 A ARP040101583 A AR P040101583A AR 044283 A1 AR044283 A1 AR 044283A1
Authority
AR
Argentina
Prior art keywords
formula
spirolactone
group
forming
acid
Prior art date
Application number
ARP040101583A
Other languages
English (en)
Original Assignee
Merck & Co Inc
Banyu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, Banyu Pharma Co Ltd filed Critical Merck & Co Inc
Publication of AR044283A1 publication Critical patent/AR044283A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicación 1: Un procedimiento para preparar un compuesto de la fórmula (1) o una sal del mismo, en el que: T, U, V y W se seleccionan cada uno independientemente del grupo que consiste en: nitrógeno; y metino; en los que el grupo metino no está sustituido o está opcionalmente sustituido con un sustituyente que se selecciona del grupo que consiste en: halógeno; alquilo inferior; hidroxi; y alcoxi inferior y en el que al menos dos de T, U, V y W son metino; que comprende las etapas de: a) formar un haluro de ácido de espirolactona de la fórmula (2), en el que X es cloro o bromo y T, U, V y W son tal como se define anteriormente, tratando el compuesto de la fórmula (1) con un agente de halogenación en un disolvente; b) formar un éster de espirolactona de la fórmula (3), en el que R3 se selecciona del grupo que consiste en terc-butilo, metilciclohexilo, metilciclopentilo y neopentilo y T, U, V y W son tal como se define anteriormente, tratando el haluro de ácido de espirolactona de la fórmula (2) con una base y un alcohol en un disolvente; c) formar un ácido de espirolactona de la fórmula (1), en el que T, U, V y W se definen como anteriormente, hidrolizando el éster de espirolactona de la fórmula (3) con un ácido acuoso; y d) aislar el producto resultante.
ARP040101583A 2003-05-19 2004-05-10 Procedimeinto para preparar compuestos de espirolactona AR044283A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47168003P 2003-05-19 2003-05-19

Publications (1)

Publication Number Publication Date
AR044283A1 true AR044283A1 (es) 2005-09-07

Family

ID=33476871

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040101583A AR044283A1 (es) 2003-05-19 2004-05-10 Procedimeinto para preparar compuestos de espirolactona

Country Status (6)

Country Link
US (1) US20060241299A1 (es)
AR (1) AR044283A1 (es)
AU (1) AU2004240933A1 (es)
CA (1) CA2526027A1 (es)
TW (1) TW200510316A (es)
WO (1) WO2004104009A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004043501A1 (de) * 2004-09-06 2006-03-09 Chemetall Gmbh Methyllithium/Lithiumbromid enthaltendes Synthesemittel und Verfahren zu dessen Herstellung
EP1912642B1 (en) 2005-07-28 2012-10-17 Merck Sharp & Dohme Corp. A crystalline form of a npy5 antagonist

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI279402B (en) * 1999-08-20 2007-04-21 Banyu Pharma Co Ltd Spiro compounds having NPY antagonistic activities and agents containing the same
PL375926A1 (en) * 2002-10-18 2005-12-12 Merck & Co, Inc. Process for making spirolactone compounds

Also Published As

Publication number Publication date
AU2004240933A1 (en) 2004-12-02
CA2526027A1 (en) 2004-12-02
US20060241299A1 (en) 2006-10-26
TW200510316A (en) 2005-03-16
WO2004104009A1 (en) 2004-12-02

Similar Documents

Publication Publication Date Title
PE20030612A1 (es) Benzoimidazoles
RS53398B (en) PROCEDURE FOR OBTAINING AMINO CROTONYL UNITS
RS51454B (en) 5,6-DIALKYL-7-AMINOTRIAZOLOPYRIMIDINES, PROCEDURES FOR THEIR PREPARATION, THEIR APPLICATION FOR THE CONTROL OF PATHOGENIC Fungi, AND THE MEANS CONTAINING THESE COMPOUNDS
AR022469A1 (es) Uso de acidos isoxazolcarboxilicos sustituidos y derivados y nuevas sustancias
CY1108334T1 (el) Υποκατασταθεισες δικετοπιπεραζινες ως ανταγωνιστες ωκυτοκινης
DOP2010000404A (es) Composiciones de peracido y 2-hidroxi acido organico y metodos para tratar productos agricolas
CO5700779A2 (es) Un proceso para la preparación de oxi-(1h)-quinolin-2-onas 5-(haloacetil)-8-sustituidas
AR007695A1 (es) Procedimiento para preparar fenilheterociclos utiles como inhibidores de cox-2
ATE331713T1 (de) Verfahren zur herstellung von 5-nitrobenzofuranen
UY27338A1 (es) Nuevos derivados de ácido sulfónico
AR030203A1 (es) Derivados de carbamato de 2-(s)-hidroximutilina, composiciones farmaceuticas que los comprenden, procedimiento para prepararlos y 2(s), 11-dihidroxi protegida-mutilina como compuesto intermediario
CA2429133A1 (en) Novel imidazole derivatives, production method thereof and use thereof
PE20010678A1 (es) Tratamiento de enfisema usando antagonistas retinoides selectivos de rar
ATE348825T1 (de) Prozess zur herstellung von dioxanessigsäureestern
AR044283A1 (es) Procedimeinto para preparar compuestos de espirolactona
SE8003278L (sv) Fenyletylaminderivat
AR059375A1 (es) Procedimiento para produccion de 5-alcoxi-4-hidroximetilpirazol y compuestos
ECSP003680A (es) Proceso para derivados del acido fenilacetico
ATE9225T1 (de) Derivate des 5-hydroxy-tetrahydro-2-furanons.
EA201071014A1 (ru) Новые 7-замещенные производные 3-карбоксиоксадиазинохинолонов, способ их получения и применение в качестве антибактериальных средств
GB1057349A (en) Water-soluble flavanoid derivatives
NO994049L (no) Metode for aa fremstille farmasöytiske forbindelser
AR016737A1 (es) Procesos para preparar derivados indazol sustituidos
AR041695A1 (es) Derivados de acilo de 5- (2- (4-(1,2- bencisotiazol-3-il) 1- piperizinil ) etil) - 6 cloro - 1, 3- dihidro - 2 h indol- 2 ona que presentan actividad neuroleptica
SE7510787L (sv) Nya kvevehaltiga, polycykliska foreningar, salter derav och deras optiska antipoder, jemte sett for deras framstellning

Legal Events

Date Code Title Description
FB Suspension of granting procedure